Zhixiang Zhuang
Overview
Explore the profile of Zhixiang Zhuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mao C, Li S, Fan R, Zhang J, Fan X, Shentu Z, et al.
Mol Pharm
. 2025 Mar;
PMID: 40088168
Cadherin 17 (CDH17) is highly expressed in digestive system cancers, and the potential of nanobodies targeting CDH17 as imaging probes and delivery vehicles for radioactive β-particles warrants exploration for their...
2.
Fan R, Mao C, Zhang J, Dai M, Zhang R, Wang X, et al.
Int J Colorectal Dis
. 2025 Feb;
40(1):53.
PMID: 40000449
Purpose: Oligometastatic colorectal cancer (OMCRC) patients can achieve long-term disease control with multidisciplinary treatment. However, the development of extensive metastasis worsens prognosis and restricts treatment options. This study aims to...
3.
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al.
Nat Med
. 2025 Jan;
PMID: 39843940
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits...
4.
Ma J, Wang J, Xu T, Ouyang Q, Wang X, Wang J, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39825877
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness...
5.
Yuan S, Zhu L, Luo Y, Chen X, Jing H, Wang J, et al.
J Drug Target
. 2024 Oct;
33(1):111-126.
PMID: 39470031
Eliciting tumour microenvironment (TME) activation in triple-negative breast cancer (TNBC) is crucial for effective anti-tumour therapies. The aim of this study is to employ pharmaceutical approaches to precisely deliver Ganoderma...
6.
Zhang J, Fan R, Mao C, Zhou X, Zhang Q, Li S, et al.
Clin Nutr ESPEN
. 2024 Jul;
63:259-266.
PMID: 38972036
Background & Aims: The association between artificial sweeteners and various cancers has been investigated, but their relationship with respiratory system cancers remains uncertain. To address this knowledge gap, we conducted...
7.
Fan R, Zhang J, Shen J, Mao C, Li S, Zhuang Z
Recent Pat Anticancer Drug Discov
. 2024 Jan;
PMID: 38243929
Background: Chronic constipation and irritable bowel syndrome (IBS) manifest as prevalent gastrointestinal disorders, while digestive tract cancers (DTCs) present formidable challenges to global well-being. However, extant observational studies proffer uncertain...
8.
Ni Y, Zhuang Z
Cell Signal
. 2023 Dec;
114:110995.
PMID: 38043669
Metabolic reprogramming allows tumor cells to meet high demand of biogenesis and increased energy for rapid proliferation. Gastric cancer (GC) ranks among the most prevalent malignancies globally. Exploring the underlying...
9.
Zhang B, Song Y, Luo S, Yin X, Li E, Wang H, et al.
Cell Rep Med
. 2023 Nov;
4(12):101301.
PMID: 38016482
We report a multicenter, phase 2 study evaluating the efficacy of pucotenlimab, an anti-PD-1 antibody, in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, and potential biomarkers for...
10.
Qiu J, Shi W, Zhang J, Gao Q, Feng L, Zhuang Z
BMC Gastroenterol
. 2023 May;
23(1):168.
PMID: 37210494
Background: Regulatory T cells (Tregs) play an important role in regulation of immune response and immunologic tolerance in cancer. Gastrointestinal cancer is still a leading cause of cancer-related death in...